Healthcare -
Biotechnology - NASDAQ - US
$ 1.36
0 %
$ 87.4 M
Market Cap
-0.88
P/E
1. INTRINSIC VALUE
Balance Sheet
Inozyme Pharma, Inc.
| Current Assets | 196 M |
| Cash & Short-Term Investments | 189 M |
| Receivables | 385 K |
| Other Current Assets | 7.28 M |
| Non-Current Assets | 4.6 M |
| Long-Term Investments | 0 |
| PP&E | 2.59 M |
| Other Non-Current Assets | 2 M |
| Current Liabilities | 14.7 M |
| Accounts Payable | 1.17 M |
| Short-Term Debt | 910 K |
| Other Current Liabilities | 12.6 M |
| Non-Current Liabilities | 45.7 M |
| Long-Term Debt | 45.7 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Inozyme Pharma, Inc.
| Revenue | 0 |
| Cost Of Revenue | 1.29 M |
| Gross Profit | -1.29 M |
| Operating Expenses | 75.6 M |
| Operating Income | -75.6 M |
| Other Expenses | -4.48 M |
| Net Income | -71.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Inozyme Pharma, Inc.
| Net Income | -71.2 M |
| Depreciation & Amortization | 833 K |
| Capital Expenditures | -298 K |
| Stock-Based Compensation | 7.04 M |
| Change in Working Capital | -3.08 M |
| Others | -6 M |
| Free Cash Flow | -71 M |
Wall Street Analysts Price Targets
Inozyme Pharma, Inc.
Wall Street analysts predict an average 1-year price target for INZY of $14.7 , with forecasts ranging from
a
low of
$14 to a high of $16 .
INZY Lowest Price Target
Wall Street Target
14 USD
929.41%
INZY Average Price Target
Wall Street Target
14.7 USD
978.43%
INZY Highest Price Target
Wall Street Target
16 USD
1076.47%
4. DIVIDEND
ANALYSIS
INZY does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Inozyme Pharma, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
52.2 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
9 months ago
Apr 02, 2024
|
Sell 52.2 K
USD
|
Treco Douglas A
CEO
|
- 7523
|
6.94 USD |
|
1 year ago
Aug 01, 2023
|
Bought
571 K USD
|
Pivotal bioVenture Partners Fund I, L.P.
Director
|
+ 119048
|
4.8 USD |
|
1 year ago
Aug 01, 2023
|
Bought
3.43 M USD
|
Pivotal bioVenture Partners Fund I, L.P.
Director
|
+ 714285
|
4.8 USD |
|
1 year ago
Aug 01, 2023
|
Bought
571 K USD
|
Hopfner Robert Lorne
Director
|
+ 119048
|
4.8 USD |
|
1 year ago
Aug 01, 2023
|
Bought
3.43 M USD
|
Hopfner Robert Lorne
Director
|
+ 714285
|
4.8 USD |
|
1 year ago
May 12, 2023
|
Bought
1.43 M USD
|
Hopfner Robert Lorne
Director
|
+ 228702
|
6.25 USD |
|
1 year ago
May 11, 2023
|
Bought
1.42 M USD
|
Hopfner Robert Lorne
Director
|
+ 219230
|
6.48 USD |
|
1 year ago
Mar 29, 2023
|
Bought
1.56 M USD
|
Hopfner Robert Lorne
Director
|
+ 344592
|
4.5379 USD |
|
1 year ago
Mar 28, 2023
|
Bought
652 K USD
|
Hopfner Robert Lorne
Director
|
+ 156766
|
4.1612 USD |
|
1 year ago
Mar 27, 2023
|
Bought
189 K USD
|
Hopfner Robert Lorne
Director
|
+ 51074
|
3.6952 USD |
|
2 years ago
Dec 15, 2022
|
Bought
29.9 K USD
|
Bjarke Henric Bjorn
SVP, COO
|
+ 21500
|
1.39 USD |
|
2 years ago
Apr 19, 2022
|
Bought
5 M USD
|
ENRIGHT PATRICK G
director:
|
+ 1355000
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
5 M USD
|
Longitude Capital Partners III, LLC
10 percent owner
|
+ 1355000
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
3.95 M USD
|
Pivotal bioVenture Partners Fund I U.G.P., Ltd
director:
|
+ 1070000
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
3.95 M USD
|
Pivotal bioVenture Partners Fund I, L.P.
Director
|
+ 1070000
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
100 K USD
|
Bjarke Henric Bjorn
SVP, COO
|
+ 27100
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
250 K USD
|
Bolte Axel
Chief Executive Officer
|
+ 67750
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
3.95 M USD
|
Hopfner Robert Lorne
director:
|
+ 1070000
|
3.69 USD |
|
2 years ago
Apr 19, 2022
|
Bought
100 K USD
|
Subramanian Sanjay
SVP, CFO
|
+ 27100
|
3.69 USD |
|
3 years ago
Jun 24, 2021
|
Sell 6.68
USD
|
Bolte Axel
Chief Executive Officer
|
- 66788
|
0.0001 USD |
|
3 years ago
Jan 28, 2021
|
Sell 7.88 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 375000
|
21 USD |
|
4 years ago
Jul 28, 2020
|
Bought
6 M USD
|
Novo Holdings A/S
10 percent owner
|
+ 375000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
1.3 M USD
|
Sanofi
10 percent owner
|
+ 81250
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
384 K USD
|
Rock Springs Capital Management LP
10 percent owner
|
+ 24000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
9.22 M USD
|
Rock Springs Capital Management LP
10 percent owner
|
+ 576000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
9.6 M USD
|
RA CAPITAL MANAGEMENT, L.P.
10 percent owner
|
+ 600000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
Sonsini Peter W.
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
SANDELL SCOTT D
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
MAKOWER JOSHUA
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
Makhzoumi Mohamad
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
Florence Anthony A. Jr.
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
BASKETT FOREST
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
4 M USD
|
New Enterprise Associates 15, L.P.
10 percent owner
|
+ 250000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
10 M USD
|
Longitude Capital Partners III, LLC
10 percent owner
|
+ 625000
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
3 M USD
|
Pivotal bioVenture Partners Fund I, L.P.
10 percent owner
|
+ 187500
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
3 M USD
|
Hopfner Robert Lorne
director, 10 percent owner:
|
+ 187500
|
16 USD |
|
4 years ago
Jul 28, 2020
|
Bought
7 M USD
|
Sofinnova Venture Partners X, L.P.
10 percent owner
|
+ 437500
|
16 USD |
7. News
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
globenewswire.com
- 1 month ago
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 2 months ago
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences:
globenewswire.com
- 2 months ago
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –
globenewswire.com
- 2 months ago
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -
globenewswire.com
- 2 months ago
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company's ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) receiving hemodialysis will be presented during a poster session at the American Society of Nephrology (ASN) Kidney Week 2024, which is being held October 24-27, 2024, in San Diego.
globenewswire.com
- 3 months ago
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry.
globenewswire.com
- 3 months ago
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, “This under-the-radar stock could be worth a look ahead of it.”
benzinga.com
- 4 months ago
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 from 3:45-4:20 pm ET.
globenewswire.com
- 4 months ago
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024. Fast Track Designation given by the FDA for the use of INZ-701 for the treatment of patients with ABCC6 Deficiency. Meeting with FDA to discuss potential of initiating a pivotal late-stage study using INZ-701 for the treatment of pediatric patients with ABCC6 Deficiency, expected end of 2024.
seekingalpha.com
- 5 months ago
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT -
globenewswire.com
- 5 months ago
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
globenewswire.com
- 6 months ago
8. Profile
Summary
Inozyme Pharma, Inc. INZY
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 87.4 M
Dividend Yield
0.00%
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Contact
321 Summer Street, Boston, MA, 02210
https://www.inozyme.com
IPO
Date
July 24, 2020
Employees
59
Officers
Dr. David Thompson M.A., M.S., Ph.D.
Senior Vice President, Chief Scientific Officer & Chief Development Officer
Mr. Axel Bolte M.B.A., M.Sc.
Co-Founder, Senior Advisor & Director
Mr. Stefan Riley
Director of Investor Relations
Ms. Gayle Gironda
Senior Vice President & Chief People Officer
Dr. Matthew Winton Ph.D.
Senior Vice President & Chief Operating Officer
Dr. Douglas A. Treco Ph.D.
Chief Executive Officer & Chairman
Dr. Soojin Kim Ph.D.
Senior Vice President & Chief Technical Operations Officer
Mr. Sanjay S. Subramanian M.B.A., M.S.
Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Corporate Secretary
Dr. Demetrios Braddock M.D., Ph.D.
Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
Dr. Yves Sabbagh Ph.D.
Chairman of Scientific Advisory Board & Senior Vice President